CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study

被引:40
作者
Prasad, ML
Pellegata, NS
Kloos, RT
Barbacioru, C
Huang, Y
de la Chapelle, A
机构
[1] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA
[2] Ohio State Univ, Human Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA
关键词
D O I
10.1089/105072504773297830
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Molecular markers of papillary thyroid carcinoma (PTC) are relatively unknown. Recently, the CITED1 gene was reported to be greatly upregulated in PTC relative to normal thyroid. The CITED1 protein, a 27-kd transcriptional transactivator nuclear protein is expressed in PTC, melanocytes, breast epithelial cells, and several embryonic tissues. However, its expression in other thyroid masses and non-thyroid tumors is not known. We evaluated CITED1 protein expression in tissue microarrays comprising various thyroid and nonthyroid tissues by immunohistochemistry using a polyclonal anti-CITED1 antibody. CITED1 expression was seen in 63 of 68 PTC (93%), 3 of 12 follicular carcinomas (25%), 2 of 7 Hurthle cell carcinomas (28%), 2 of 21 adenomas (10%), 2 of 6 follicular neoplasms of undetermined malignant behavior (33%), and 2 of 24 nodular goiters (8%). Normal thyroids (n = 27), thyrotoxic hyperplasias (n = 14), and anaplastic thyroid carcinomas (n = 5) did not express CITED1 Among nonthyroid tumors, 6 of 23 melanomas (26%), 11 of 65 prostatic carcinomas (17%), 3 of 25 glioblastomas (12%), 4 of 67 breast carcinomas (6%), 1 of 49 lymphomas (2%), 1 of 65 lung carcinomas (2%), 1 of 68 colon carcinomas (2%), and none of 49 ovarian carcinomas (0%) expressed CITED1 The accuracy of CITED1 in differentiating PTC from benign thyroid nodules, other thyroid carcinomas, and nonthyroid carcinomas was 93%, 89%, and 94%, respectively. CITED1 is preferentially expressed in PTC and may be used as a diagnostic marker of it.
引用
收藏
页码:169 / 175
页数:7
相关论文
共 26 条
[1]  
ALTMAN DG, 1996, PRACTICAL STAT MED R, P404
[2]   Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules [J].
Beesley, MF ;
McLaren, KM .
HISTOPATHOLOGY, 2002, 41 (03) :236-243
[3]  
Castronovo V, 1996, J PATHOL, V179, P43, DOI 10.1002/(SICI)1096-9896(199605)179:1<43::AID-PATH541>3.0.CO
[4]  
2-N
[5]   Immunohistochemical diagnosis of papillary thyroid carcinoma [J].
Cheung, CC ;
Ezzat, S ;
Freeman, JL ;
Rosen, IB ;
Asa, SL .
MODERN PATHOLOGY, 2001, 14 (04) :338-342
[6]   HISTOLOGICAL-EVALUATION OF THYROID CARCINOMAS - REPRODUCIBILITY OF THE WHO CLASSIFICATION [J].
FASSINA, AS ;
MONTESCO, MC ;
NINFO, V ;
DENTI, P ;
MASAROTTO, G .
TUMORI JOURNAL, 1993, 79 (05) :314-320
[7]   MSG1 (melanocyte-specific gene 1):: mapping to chromosome Xq13.1, genomic organization, and promoter analysis [J].
Fenner, MH ;
Parrish, JE ;
Boyd, Y ;
Reed, V ;
MacDonald, M ;
Nelson, DL ;
Isselbacher, KJ ;
Shioda, T .
GENOMICS, 1998, 51 (03) :401-407
[8]   Observer variation of lesions of the thyroid [J].
Franc, B .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (08) :1177-1178
[9]   Observer variation of encapsulated follicular lesions of the thyroid gland [J].
Hirokawa, M ;
Carney, JA ;
Goellner, JR ;
DeLellis, RA ;
Heffess, CS ;
Katoh, R ;
Tsujimoto, M ;
Kakudo, K .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (11) :1508-1514
[10]   Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays [J].
Hoos, A ;
Stojadinovic, A ;
Singh, B ;
Dudas, ME ;
Leung, DHY ;
Shaha, AR ;
Shah, JP ;
Brennan, MF ;
Cordon-Cardo, C ;
Ghossein, R .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (01) :175-183